This work is licensed under a Creative Commons Attribution 4.0 International License.
hBD3-3 M2
General Information
DRACP ID DRACP01165
Peptide Name hBD3-3 M2
Sequence GKCSTRGRKMCRRKK
Sequence Length 15
UniProt ID Not available
PubChem CID Not available
Origin Not available
Type Synthetic peptide
Classification
Active ACP
Activity Information
| Cell Line | Disease | Cancer Classified | Activity | Assay | Testing Time | Literature |
|---|---|---|---|---|---|---|
| hBCSCs (human Breast Cancer Stem cells, Celprogen, USA;positive for CD44) | human Breast Cancer Stem cells | Carcinoma | As show in fig3 | Western blot analysis assay | Not available | Patent |
Hemolytic Activity Not available
Normal (non-cancerous) Cytotoxicity Not available
Target Not available
Affinity Not available
Mechanism Not available
Nature Anticancer
Structure Information
Helicity Not available
Linear/Cyclic Linear
Disulfide/Other Bond Not available
N-terminal Modification Free
C-terminal Modification Free
Other Modification None
Chiral L
Physicochemical Information
Formula C70H135N31O18S3
Absent amino acids ADEFHILNPQVWY
Common amino acids KR
Mass 204510
Pl 12.12
Basic residues 8
Acidic residues 0
Hydrophobic residues 0
Net charge 8
Boman Index -8106
Hydrophobicity -193.33
Aliphatic Index 0
Half Life
Mammalian: 30 hour
Yeast: >20 hour
E.coli: >10 hour
Extinction Coefficient cystines 125
Absorbance 280nm 8.93
Polar residues 6
Amino acid distribution
Literature Information
Literature 1
Pubmed ID Not available
Title Not available
Doi Not available
Year Not available
Patent
Patent ID EP3111951B1
Patent Title Anticancer Functional Peptide for the Treatment of Breast Cancer
Other Iinformation Granted Patent; Family: 9s / 9ex; Family Jurisdictions: KR, US, WO, ES, EP; Legal Status: Active; Application No: 16736753; Filed: Mar 3, 2016; Published: Dec 11, 2019; Earliest Priority: Mar 26, 2015; Granted: Dec 11, 2019
Other Published ID EP3111951A4 EP3111951B1 ES2773755T3 KR101693533B1 KR20160115314A US2017042963A1 US9993519B2 WO2016153185A1
This work is licensed under a Creative Commons Attribution 4.0 International License.